Cargando…

Gradual withdrawal of remifentanil delays initial post-operative analgesic demand after thyroid surgery; double-blinded, randomized controlled trial

BACKGROUND: Mismanagement of remifentanil leads to severe side effects such as opioid-induced tolerance and hyperalgesia. Recently studies revealed an alternative withdrawal method to limit these side effects. A gradual withdrawal of remifentanil seems to be associated with less pain. The hypothesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Saxena, Sarah, Gonsette, Kimberly, Terram, Willy, Huybrechts, Isabelle, Nahrwold, Daniel A., Cappello, Matteo, Barvais, Luc, Engelman, Edgard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485117/
https://www.ncbi.nlm.nih.gov/pubmed/31027480
http://dx.doi.org/10.1186/s12871-019-0731-9
_version_ 1783414218333093888
author Saxena, Sarah
Gonsette, Kimberly
Terram, Willy
Huybrechts, Isabelle
Nahrwold, Daniel A.
Cappello, Matteo
Barvais, Luc
Engelman, Edgard
author_facet Saxena, Sarah
Gonsette, Kimberly
Terram, Willy
Huybrechts, Isabelle
Nahrwold, Daniel A.
Cappello, Matteo
Barvais, Luc
Engelman, Edgard
author_sort Saxena, Sarah
collection PubMed
description BACKGROUND: Mismanagement of remifentanil leads to severe side effects such as opioid-induced tolerance and hyperalgesia. Recently studies revealed an alternative withdrawal method to limit these side effects. A gradual withdrawal of remifentanil seems to be associated with less pain. The hypothesis of this double-blinded, randomized controlled trial was that a gradual withdrawal of remifentanil would be associated with less immediate post-operative pain compared to after an abrupt discontinuation of remifentanil in patients who underwent thyroid surgery. METHODS: This double-blinded, randomized controlled trial was conducted in a tertiary level hospital in Brussels (Belgium) from April until August 2017. 34 patients undergoing thyroid surgery were randomized and 29 patients completed the study. After randomization, patients undergoing thyroid surgery were allocated to two groups: one with an abrupt discontinuation of remifentanil after surgery and one with a gradual withdrawal of remifentanil after surgery. The primary outcome was the initial post-operative demand of analgesic medication. RESULTS: Gradual withdrawal of remifentanil was associated with a delayed initial post-operative demand of analgesic medication (P = 0.006). The first morphine bolus was given after 76.3 +/− 89.0 min in the group with a gradual withdrawal of remifentanil versus after 9.0 +/− 13.5 min in the group with an abrupt discontinuation of remifentanil. However, overall morphine consumption, numeric rating scale scores, Ramsay Sedation Scale scores, and quality of recovery scores (QoR-40) were similar in both groups (P > 0.05). CONCLUSION: Though overall morphine consumption, numeric rating scale scores, Ramsay Sedation Scale scores, and quality of recovery scores (QoR-40) are not altered, a gradual withdrawal of remifentanil after thyroid surgery is safe and associated with a delayed initial post-operative demand of analgesic drugs. The withdrawal process does, however, require vigilance and training. TRIAL REGISTRATION: Clinicaltrials.gov NCT03110653 (PI: Luc Barvais; date of registration: 03/31/2017).
format Online
Article
Text
id pubmed-6485117
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64851172019-05-03 Gradual withdrawal of remifentanil delays initial post-operative analgesic demand after thyroid surgery; double-blinded, randomized controlled trial Saxena, Sarah Gonsette, Kimberly Terram, Willy Huybrechts, Isabelle Nahrwold, Daniel A. Cappello, Matteo Barvais, Luc Engelman, Edgard BMC Anesthesiol Research Article BACKGROUND: Mismanagement of remifentanil leads to severe side effects such as opioid-induced tolerance and hyperalgesia. Recently studies revealed an alternative withdrawal method to limit these side effects. A gradual withdrawal of remifentanil seems to be associated with less pain. The hypothesis of this double-blinded, randomized controlled trial was that a gradual withdrawal of remifentanil would be associated with less immediate post-operative pain compared to after an abrupt discontinuation of remifentanil in patients who underwent thyroid surgery. METHODS: This double-blinded, randomized controlled trial was conducted in a tertiary level hospital in Brussels (Belgium) from April until August 2017. 34 patients undergoing thyroid surgery were randomized and 29 patients completed the study. After randomization, patients undergoing thyroid surgery were allocated to two groups: one with an abrupt discontinuation of remifentanil after surgery and one with a gradual withdrawal of remifentanil after surgery. The primary outcome was the initial post-operative demand of analgesic medication. RESULTS: Gradual withdrawal of remifentanil was associated with a delayed initial post-operative demand of analgesic medication (P = 0.006). The first morphine bolus was given after 76.3 +/− 89.0 min in the group with a gradual withdrawal of remifentanil versus after 9.0 +/− 13.5 min in the group with an abrupt discontinuation of remifentanil. However, overall morphine consumption, numeric rating scale scores, Ramsay Sedation Scale scores, and quality of recovery scores (QoR-40) were similar in both groups (P > 0.05). CONCLUSION: Though overall morphine consumption, numeric rating scale scores, Ramsay Sedation Scale scores, and quality of recovery scores (QoR-40) are not altered, a gradual withdrawal of remifentanil after thyroid surgery is safe and associated with a delayed initial post-operative demand of analgesic drugs. The withdrawal process does, however, require vigilance and training. TRIAL REGISTRATION: Clinicaltrials.gov NCT03110653 (PI: Luc Barvais; date of registration: 03/31/2017). BioMed Central 2019-04-25 /pmc/articles/PMC6485117/ /pubmed/31027480 http://dx.doi.org/10.1186/s12871-019-0731-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Saxena, Sarah
Gonsette, Kimberly
Terram, Willy
Huybrechts, Isabelle
Nahrwold, Daniel A.
Cappello, Matteo
Barvais, Luc
Engelman, Edgard
Gradual withdrawal of remifentanil delays initial post-operative analgesic demand after thyroid surgery; double-blinded, randomized controlled trial
title Gradual withdrawal of remifentanil delays initial post-operative analgesic demand after thyroid surgery; double-blinded, randomized controlled trial
title_full Gradual withdrawal of remifentanil delays initial post-operative analgesic demand after thyroid surgery; double-blinded, randomized controlled trial
title_fullStr Gradual withdrawal of remifentanil delays initial post-operative analgesic demand after thyroid surgery; double-blinded, randomized controlled trial
title_full_unstemmed Gradual withdrawal of remifentanil delays initial post-operative analgesic demand after thyroid surgery; double-blinded, randomized controlled trial
title_short Gradual withdrawal of remifentanil delays initial post-operative analgesic demand after thyroid surgery; double-blinded, randomized controlled trial
title_sort gradual withdrawal of remifentanil delays initial post-operative analgesic demand after thyroid surgery; double-blinded, randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485117/
https://www.ncbi.nlm.nih.gov/pubmed/31027480
http://dx.doi.org/10.1186/s12871-019-0731-9
work_keys_str_mv AT saxenasarah gradualwithdrawalofremifentanildelaysinitialpostoperativeanalgesicdemandafterthyroidsurgerydoubleblindedrandomizedcontrolledtrial
AT gonsettekimberly gradualwithdrawalofremifentanildelaysinitialpostoperativeanalgesicdemandafterthyroidsurgerydoubleblindedrandomizedcontrolledtrial
AT terramwilly gradualwithdrawalofremifentanildelaysinitialpostoperativeanalgesicdemandafterthyroidsurgerydoubleblindedrandomizedcontrolledtrial
AT huybrechtsisabelle gradualwithdrawalofremifentanildelaysinitialpostoperativeanalgesicdemandafterthyroidsurgerydoubleblindedrandomizedcontrolledtrial
AT nahrwolddaniela gradualwithdrawalofremifentanildelaysinitialpostoperativeanalgesicdemandafterthyroidsurgerydoubleblindedrandomizedcontrolledtrial
AT cappellomatteo gradualwithdrawalofremifentanildelaysinitialpostoperativeanalgesicdemandafterthyroidsurgerydoubleblindedrandomizedcontrolledtrial
AT barvaisluc gradualwithdrawalofremifentanildelaysinitialpostoperativeanalgesicdemandafterthyroidsurgerydoubleblindedrandomizedcontrolledtrial
AT engelmanedgard gradualwithdrawalofremifentanildelaysinitialpostoperativeanalgesicdemandafterthyroidsurgerydoubleblindedrandomizedcontrolledtrial